![neostem_logo[1]](http://www.scimitarequity.com/blog/wp-content/uploads/neostem_logo1-e1288874670666.jpg){kind=logo}
Blessing the open dialogue and laying the groundwork for collaboration Read more…
VSELs might be an ideal cell therapy Read more…
Adds $12.3 M in Non-Dilutive Cash to and Removes Over $30 M of Debt from its Balance Sheet … Read more…
NBS currently conducting a large P2 in AMI plans to initiate a trial in CHF… Read more…
Significant Expansion in its Claims Granted to Protect the Use of CD34+ Cells Read more…
Amex: NBS is UP +$0.0449 or +6.75% to $0.71 in pre-market trading Read more…
Net loss of $20.59M or $0.15 per share Read more…
Updates and Highlights Read more…
Progenitor Cell Therapy (PCT) and SOTIO Enter Into a P3 Manufacturing Services Agreement Read more…
Robin Smith’s multifaceted business strategy Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.